Varenicline tartrate
α4ß2 partial agonist / Smoking cessation aid / Varenicline is a partial agonist of the α4β2 neuronal nicotinic acetylcholine receptor (EC50 = 2.3 µM) and a full agonist at α7 neuronal nicotinic receptors.1 Clinically useful smoking cessation agent.2,3
Biochemicals & reagents
375815-87-5
Chantix; CP-526,555-18
1) Mihalak et al. (2006), Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors; Mol. Pharmacol. 70 801 2) Rollema et al. (2007), Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid; Neuropharmacology 52 985 3) Mills et al. (2012), Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systemic review and multiple treatment meta-analysis; Ann. Med. 44 588
-20°C
TARGET: Acetylcholinesterase/Butyrylcholinesterase -- PATHWAY: ACh (Acetylcholine) signaling -- RESEARCH AREA: Neuroscience